Will Merck report Keytruda H2 2026 sales up over 10% vs H2 2025 by 31 Oct 2026?
Posted 2026-09-11, stated before the outcome.
Merck & Co. is a multinational pharmaceutical company that develops and markets Keytruda, an immunotherapy drug. Quarterly earnings reports disclose revenue figures for specific products, allowing investors to track sales growth over time.
The claim
Merck will announce that Keytruda sales in the second half of 2026 exceed the second half of 2025 by more than 10% in its Q3 2026 earnings report released by 2026-10-31.
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.